You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 24, 2024

Details for Patent: 5,756,287


✉ Email this page to a colleague

« Back to Dashboard


Title: High affinity HIV integrase inhibitors
Abstract:Methods are described for the identification and preparation of nucleic acid ligands to HIV integrase. Included in the invention are specific RNA ligands to HIV integrase identified by the SELEX method. Also included in the invention are specific RNA ligands that are inhibitors of HIV integrase.
Inventor(s): Allen; Patrick (Boulder, CO), Gold; Larry (Boulder, CO)
Assignee: NeXstar Pharmaceuticals, Inc. (Boulder, CO)
Filing Date:Dec 21, 1994
Application Number:08/361,795
Claims:1. A method of identifying nucleic acid ligands to a target molecule comprising:

a) contacting a candidate mixture with the target molecule, wherein nucleic acids having an increased affinity to the target molecule relative to the candidate mixture may be partitioned from the remainder of the candidate mixture and wherein the candidate mixture comprises a first and a second pool of nucleic acids, wherein the first pool of nucleic acid is amplifiable and the second pool of nucleic acids is non-amplifiable;

b) partitioning the increased affinity nucleic acids from the remainder of the candidate mixture; and

c) amplifying the increased affinity nucleic acids under conditions wherein only the first pool of nucleic acids is amplified, to yield a ligand enriched mixture of nucleic acids whereby nucleic acid ligands to the target molecule may be identified.

2. The method of claim 1, further comprising:

d) repeating steps a), b), and c).

3. A method of identifying nucleic acid ligands to HIV integrase, comprising:

a) contacting a candidate mixture of nucleic acids with HIV integrase, wherein nucleic acids having an increased affinity to the HIV integrase relative to the candidate mixture may be partitioned from the remainder of the candidate mixture; and

b) partitioning the increased affinity nucleic acids from the remainder of the candidate mixture; and

c) amplifying the increased affinity nucleic acids to yield a mixture of nucleic acids enriched for nucleic acid sequences with relatively higher affinity and specificity for binding to HIV integrase, whereby nucleic acid ligands of HIV integrase may be identified.

4. The method of claim 3 further comprising:

d) repeating steps a), b) and c).

5. The method of claim 3, wherein the candidate mixture that is contacted with the target molecule includes non-amplifiable nucleic acids.

6. The method of claim 3 wherein said candidate mixture of nucleic acids is comprised of single stranded nucleic acids.

7. The method of claim 6 wherein said single stranded nucleic acids are ribonucleic acids.

8. The method of claim 7 wherein said nucleic acids are 2'-amino (2'-NH.sub.2) ribonucleic acids.

9. The method of claim 3, wherein said HIV integrase is HIV-1 integrase.

10. The method of claim 5, wherein said HIV integrase is HIV-1 integrase.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.